Cite
MLA Citation
Pedro Lowenstein et al.. “ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM.” Neuro-oncology, vol. 21, n.d., p. vi11. http://access.bl.uk/ark:/81055/vdc_100101668512.0x000033